350 related articles for article (PubMed ID: 20723330)
1. [Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics].
Han TJ; Xu XP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1063-8. PubMed ID: 20723330
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.
Gaidzik V; Döhner K
Semin Oncol; 2008 Aug; 35(4):346-55. PubMed ID: 18692685
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
6. Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.
Lin TL; Smith BD
Am J Med Sci; 2011 May; 341(5):404-8. PubMed ID: 21522052
[TBL] [Abstract][Full Text] [Related]
7. Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
Martelli MP; Sportoletti P; Tiacci E; Martelli MF; Falini B
Blood Rev; 2013 Jan; 27(1):13-22. PubMed ID: 23261068
[TBL] [Abstract][Full Text] [Related]
8. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD; Bullinger L
Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
[TBL] [Abstract][Full Text] [Related]
9. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
Falini B; Martelli MP
Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
Marcucci G; Mrózek K; Bloomfield CD
Curr Opin Hematol; 2005 Jan; 12(1):68-75. PubMed ID: 15604894
[TBL] [Abstract][Full Text] [Related]
11. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.
Creutzig U; Zimmermann M; Reinhardt D; Rasche M; von Neuhoff C; Alpermann T; Dworzak M; Perglerová K; Zemanova Z; Tchinda J; Bradtke J; Thiede C; Haferlach C
Cancer; 2016 Dec; 122(24):3821-3830. PubMed ID: 27529519
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
Zidan MA; Kamal Shaaban HM; Elghannam DM
Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
[TBL] [Abstract][Full Text] [Related]
13. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.
Ghanem H; Tank N; Tabbara IA
Am J Hematol; 2012 Jan; 87(1):69-77. PubMed ID: 22072438
[TBL] [Abstract][Full Text] [Related]
15. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
[TBL] [Abstract][Full Text] [Related]
16. Clinically useful prognostic factors in acute myeloid leukemia.
Ferrara F; Palmieri S; Leoni F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):181-93. PubMed ID: 17996460
[TBL] [Abstract][Full Text] [Related]
17. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
19. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]